Sunwin Stevia International (SUWN)

Overall impact
B (77)

Commentary

Sunwin Stevia International is a strong overall performer. With a 'B' rating of 76.6 for overall impact (91st percentile compared to all companies), Sunwin Stevia International ranks 110th out of 585 industry peers, behind Biogen, Amgen, Regeneron Pharmaceuticals and 106 others, and ahead of Grifols, Ionis Pharmaceuticals, Gilead Sciences and 472 others. On top material causes for Sunwin Stevia International's industry (Pharmaceuticals & Biotech), Sunwin Stevia International performs well in Accountable Institutions (87.2 score), Sustainable Use of Water (95.6), Improved Mental Health (91.5) and 8 other causes where it received an 'A' score and performs poorly in Reduced Green House Gas Emissions (35.5 score), Technology Innovation (8.2) and Disaster Readiness and Effective Aid (39.1).
Impact
Cause SUWN
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Employees
242
Sector
Health Care
Industry
Biotechnology
Sub-industry
Biotechnology
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
China
Share classes
SUWN
Description
Sunwin Stevia International, Inc. produces and sells natural sweeteners and other pharmaceutical products primarily in the People's Republic of China. It operates through two segments, Stevioside; and Corporate and Other Pharmaceutical. The company produces and sells various steviol glycosides with rebaudioside A and stevioside as the principal components. It offers Steviosin, a low calorie stevia extract for medicinal use; and OnlySweet, a zero calorie, tabletop sweetener to food and drug manufacturers, and ingredient distributor foreign trade companies. The company also produces and sells Metformin, a medication for the treatment of type 2 diabetes. Sunwin Stevia International, Inc. is based in Qufu, China.
Material causes
Ethos considers the following causes material for Sunwin Stevia International, based on its industry sub-industry Biotechnology. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.